How to Use Nebulized Antibiotics in Severe Respiratory Infections

Area of Science:

• Pulmonary Medicine
• Infectious Diseases
• Pharmacology

Background:

• Multidrug-resistant (MDR) pulmonary infections pose a growing global health threat, leading to significant morbidity and mortality.
• Nebulized antibiotics are emerging as a potential treatment strategy for these challenging infections.
• Current evidence shows a gap between extensive experimental data and limited clinical validation for nebulized antibiotic therapy.

Purpose of the Study:

• To review the existing evidence on the use of nebulized antibiotics for severe respiratory tract infections.
• To assess the potential benefits and limitations of nebulized antibiotic administration in managing multidrug-resistant pathogens.

Main Methods:

• This study is a narrative review of current literature.
• It synthesizes experimental and clinical data on nebulized antibiotic use for respiratory infections.

Main Results:

• Nebulized antibiotics can achieve higher drug concentrations directly at the infection site.
• This administration route may minimize systemic adverse effects compared to parenteral or oral routes.
• There is a notable lack of robust clinical studies confirming efficacy and safety.

Conclusions:

• Nebulized antibiotics show promise for treating difficult-to-treat pulmonary infections caused by multidrug-resistant pathogens.
• Further well-designed clinical trials are essential to establish definitive efficacy and safety profiles.